BIOTIME INC Form 4 January 22, 2016

FORM 4

OMB APPROVAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

January 31, Expires: 2005

SECURITIES

Estimated average burden hours per response... 0.5

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Add KINGSLEY A	*	ing Person *	2. Issuer Name and Ticker or Trading Symbol BIOTIME INC [BTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction	(Check all applicable)		
150 E. 57TH STREET			(Month/Day/Year) 01/20/2016	_X_ Director _X_ 10% Owner _X_ Officer (give title Other (specify below) See Remarks		
(Street)			4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
NEW YORK, NY 10022			Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		

(City)	(State)	(Zip) Tab	le I - Non-	Derivative S	ecurit	ies Acq	uired, Disposed o	f, or Beneficia	ally Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securitie on(A) or Disp (Instr. 3, 4	osed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares, no par value	01/20/2016		S	300,000	D	\$ 2.35	5,638,055 (2)	D	
Common Shares, no par value							1,506,905	I	By Greenbelt Corp.
Common Shares, no par value							375,351	I	By Greenway Partners, LP

Edgar Filing: BIOTIME INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pric Deriva Securi (Instr.
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Option to Purchase Common Shares	\$ 3.57					(3)	06/30/2020	Common Shares	50,000	
Option to Purchase Common Shares	\$ 3.11					<u>(4)</u>	06/30/2019	Common Shares	50,000	
Option to Purchase Common Shares	\$ 4.13					<u>(5)</u>	06/30/2018	Common Shares	50,000	
Option to Purchase Common Shares	\$ 4.6					<u>(6)</u>	06/30/2017	Common Shares	50,000	
Option to Purchase Common Shares	\$ 5.13					<u>(7)</u>	06/30/2016	Common Shares	50,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			

Reporting Owners 2

Edgar Filing: BIOTIME INC - Form 4

KINGSLEY ALFRED D 150 E. 57TH STREET NEW YORK, NY 10022

X See Remarks

Signatures

/s/ Alfred D. Kingsley

01/22/2016

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The securities were sold in a private transaction.
- (2) Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
- (3) 12,500 options became exercisable on September 30, 2015 and December 31, 2015, and the remaining 25,000 options will become exercisable in 2 equal quarterly installments based upon continued service on the board of directors.
- (4) 12,500 options became exercisable on September 30, 2014; December 31, 2014; March 31, 2015; and June 30, 2015.
- (5) 12,500 options became exercisable on September 30, 2013; December 31, 2013; March 31, 2014; and June 30, 2014.
- (6) 12,500 options became exercisable on September 30, 2012; December 31, 2012; March 31, 2013; and June 30, 2013.
- (7) 12,500 options became exercisable on September 30, 2011; December 31, 2011; March 31, 2012; and June 30, 2012.

Remarks:

Mr. Kingsley is Executive Chairman of certain BioTime subsidiaries.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3